Journal
THORAX
Volume 71, Issue 2, Pages 187-189Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/thoraxjnl-2015-207326
Keywords
-
Categories
Funding
- Medical Research Council [MR/M016579/1]
- MRC [MR/M016579/1, G0900453, G0400473] Funding Source: UKRI
- Asthma UK [CH11SJ] Funding Source: researchfish
- Medical Research Council [MR/M016579/1, G1000758B, G1000758, G0900453, G0400473, G0800766] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0514-10085, NF-SI-0512-10018, NF-SI-0513-10040, NF-SI-0510-10249] Funding Source: researchfish
Ask authors/readers for more resources
The UK Refractory Asthma Stratification Programme (RASP-UK) will explore novel biomarker stratification strategies in severe asthma to improve clinical management and accelerate development of new therapies. Prior asthma mechanistic studies have not stratified on inflammatory phenotype and the understanding of pathophysiological mechanisms in asthma without Type 2 cytokine inflammation is limited. RASP-UK will objectively assess adherence to corticosteroids (CS) and examine a novel composite biomarker strategy to optimise CS dose; this will also address what proportion of patients with severe asthma have persistent symptoms without eosinophilic airways inflammation after progressive CS withdrawal. There will be interactive partnership with the pharmaceutical industry to facilitate access to stratified populations for novel therapeutic studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available